Xeomin in Miami: The Purified Neurotoxin & Botox Resistance

Three months ago it worked beautifully. This time, the lines came back at week eight. Then week six. And now you are sitting at your laptop typing Xeomin Miami into Google, wondering whether a different neurotoxin is the answer.

It is one of the most common questions we hear from patients who have been treating for years, and it deserves a more careful answer than “yes, switch brands.” Xeomin is a genuinely distinctive product, and the reason people seek it out — the idea that a purer formulation is less likely to stop working over time — is grounded in real science. But the science is more nuanced than the internet makes it sound, and the assumption that a weakening result means antibody resistance is wrong more often than it is right.

Here is what Xeomin actually is, what the “naked toxin” concept does and does not mean for you, and how we approach this conversation at SkinUp in Kendall.

A note on what we carry: SkinUp offers Botox, Dysport, and Daxxify. We do not currently stock Xeomin. We are writing this guide anyway, because the question behind the search matters more than the brand name — and because, as you will see below, one of the products we do carry satisfies the same formulation criterion patients are usually looking for when they ask about Xeomin.

What Xeomin Actually Is

Xeomin is the brand name for incobotulinumtoxinA, manufactured by Merz. Like Botox, Dysport, Jeuveau, and Daxxify, it is a botulinum toxin type A product: it temporarily relaxes the specific muscles responsible for dynamic expression lines by interrupting the signal between nerve and muscle.

The regulatory timeline is worth knowing, because it tells you how much clinical history sits behind it:

• July 2010 — FDA approval for therapeutic use (cervical dystonia and blepharospasm)
• July 2011 — FDA approval for moderate to severe glabellar lines, the cosmetic indication most people mean
• July 2024 — FDA approval as the first neurotoxin cleared for the simultaneous treatment of the three upper-face areas: frown lines, forehead lines, and crow’s feet

In practical terms, Xeomin behaves much like Botox. Onset is typically 3 to 4 days, full effect settles around two weeks, and duration runs about 3 to 4 months. In clinical practice it is dosed at an approximately 1:1 ratio with Botox, which makes transferring between the two relatively straightforward.

One important qualification, because it is the kind of thing marketing copy skips: FDA labeling is explicit that potency units are specific to each product’s own preparation and assay method, and cannot be compared to or converted into the units of any other botulinum toxin product. So treat 1:1 as a practical starting point your injector adjusts from — not a fixed conversion, and never a basis for comparing prices by unit count across brands.

If you want the full landscape rather than a single product, our complete guide to neurotoxins in Miami compares the five most widely used options side by side.

The “Naked” Formulation: What Complexing Proteins Actually Are

This is the part that makes Xeomin distinctive, and it is worth explaining properly rather than repeating the marketing shorthand.

Botulinum toxin as produced by the bacterium does not arrive alone. The active 150-kilodalton neurotoxin comes bundled with a set of accessory bacterial proteins — the complexing proteins — that shield it in nature. Traditional formulations like Botox and Dysport retain some of these proteins. Xeomin is manufactured to strip them away, leaving only the active core neurotoxin. That is where the nickname comes from: the naked toxin.

Two findings from the research literature are relevant here:

1. Complexing proteins do not contribute to the drug’s therapeutic effect or its stability. They are along for the ride, not doing work. This is well demonstrated — Xeomin remains stable at room temperature before reconstitution, without the refrigeration that complexing proteins were once assumed to help provide.
2. They are a leading hypothesis in antibody formation — not a settled one. Bacterial accessory proteins may act as adjuvants, raising the total antigenic load presented to the immune system. It is worth being precise here, because this point is routinely overstated: neutralizing antibodies target the active 150-kilodalton neurotoxin itself, not the accessory proteins, and no trial has isolated their removal as the single variable that reduces clinical resistance.

That second point is the reason most patients search for Xeomin, so it deserves an honest weighting. More than a decade of clinical experience — including studies in patients with cervical dystonia who had already developed partial treatment failure on complexing-protein-containing formulations — is consistent with a complexing-protein-free product being the lower-immunogenicity choice. That is a reasonable inference from observed outcomes. It is not a demonstrated mechanism, and it is not a promise that the result will hold.

One clarification that often gets lost: complexing-protein-free is not the same as excipient-free. Xeomin is still formulated with human serum albumin and sucrose as stabilizers. The distinction is specifically about the bacterial accessory proteins — not about the product being additive-free.

”My Botox Stopped Working”: What Is Usually Going On

Here is where we would ask you to slow down before booking a brand switch.

When a neurotoxin worked and later stops working, clinicians call it secondary non-response. Neutralizing antibodies are one real mechanism, and they can develop even at the modest doses used in aesthetic practice — this is not a myth. But they are not the whole story. In one published series of secondary non-responders, fewer than half tested positive for neutralizing antibodies. For the majority, something else was going on.

In our experience, the more common explanations are:

• Dose drift. Muscles adapt. The 20 units that softened your glabella three years ago may genuinely be underdosing you now, especially if the muscle was strong to begin with.
• Interval creep. Booking at four months instead of three, or stretching to fit a travel schedule, means you spend more of the year in the tail end of the effect. The product did not weaken; the coverage gap widened.
• Injection pattern. Placement, depth, and dilution all change how a product behaves. Two injectors using identical unit counts can produce different results.
• Shifting baseline. Static lines — the ones visible at rest — respond only partially. Neurotoxin does soften them over time by reducing the repeated contraction that deepens them, but a deeply etched line usually improves incompletely and needs help from skin-quality work. As dynamic movement is managed over the years, that etched component becomes the visible remainder, and it can read as “the Botox stopped working” when it is really a different problem asking for a different tool, like microneedling or a resurfacing plan.
• Recall bias. Memory of an early result is often more flattering than the photographs. This is why we photograph.

Genuine antibody-mediated resistance is uncommon, and it looks distinctive: a progressive loss of effect across multiple sessions, at adequate doses, at correct intervals, confirmed clinically — not one disappointing round.

What We Carry — and Why It Covers the Same Ground

If you came to this page because you want a neurotoxin without bacterial complexing proteins, there is something you should know: Xeomin is not the only one.

The peer-reviewed classification of complexing-protein-free botulinum toxin type A products includes incobotulinumtoxinA (Xeomin) and daxibotulinumtoxinA (Daxxify) — which we do carry. Daxxify is built on the same 150-kilodalton core neurotoxin, stabilized with a synthetic 35-amino-acid peptide (RTP004) rather than the traditional route, and it is formulated without human serum albumin and without animal-derived components. For patients whose interest in Xeomin is really an interest in a purified formulation, Daxxify meets that same structural criterion — with the added characteristic that many patients experience a longer interval between treatments.

We will be honest about the limits of the evidence, because that is more useful to you than a sales pitch. Meeting the formulation criterion is not the same as a proven clinical advantage. Daxxify is a newer product, its published immunogenicity follow-up covers a much shorter treatment history than Xeomin’s decade-plus record, and reviewers have noted that some of its own excipients could carry immunogenic potential of their own. Both are reasonable choices on formulation grounds. Neither is a guarantee against non-response — and for most patients, formulation will not be the variable that decides whether treatment holds.

The full comparison of what we stock lives in our Daxxify vs. Botox vs. Dysport guide, and the treatments themselves are detailed on our wrinkle relaxer page.

How We Approach a Weakening Result at SkinUp

Aesthetic care should never be transactional, and a patient telling us their toxin is not lasting is a clinical question, not a reason to sell a different vial. Our sequence looks like this:

We start with your history. What product, what dose, what interval, which areas, over how long. Most of the answer is usually in that record before we examine anything.

We evaluate the muscle, not just the line. Movement pattern, muscle strength, and asymmetry determine whether the issue is dose or placement. A strong frontalis and a heavy brow behave very differently from the textbook.

We separate dynamic from static. If what is bothering you is etched at rest, more units will not fix it. That is a skin-quality conversation, and it usually belongs to a different treatment — which we would rather tell you honestly than treat with a product that cannot deliver it.

We adjust before we switch. Often the right move is a dosing correction or a tightened interval with the product you are already on. If a formulation change is genuinely indicated, we will discuss it — with the reasoning laid out.

This is the same whole-patient thinking we apply everywhere: the goal is a plan that holds up over years, not a result that looks good for two weeks. Our guide on how to make Botox last longer covers the maintenance side of that equation in more detail.

If You Are Searching “Xeomin Miami”: What to Ask Any Injector

Whether you end up with us or somewhere else, these are the questions worth asking any provider in Kendall, Coral Gables, or South Miami:

• What are you basing the dose on? A thoughtful answer references your anatomy and history. A vague one references a package.
• How do you document results? Standardized photography at baseline and at two weeks is how a provider knows whether something actually changed.
• What would make you recommend against treating today? A provider who has never declined a treatment is not evaluating.
• If this does not hold, what is your next step? You want to hear an assessment plan, not an immediate brand swap.
• Who is injecting? Credentials matter. Our guide on choosing a Botox injector in Miami covers what to verify and what should give you pause.

SkinUp Aesthetics and Wellness is located at 9789 SW 72nd St, Miami, FL 33173, at the intersection of the Kendall, Westchester, and South Miami communities — roughly 10 to 15 minutes from Coral Gables along SW 72nd Street or US-1. Patients come to us from across South Miami-Dade for exactly this kind of conversation.

For what neurotoxin treatment costs here, see our Botox cost guide for Miami — we keep pricing in the guides rather than scattered through educational content.

The Honest Summary

Xeomin is a well-established, complexing-protein-free neurotoxin with a strong safety record and a legitimate rationale behind it. If a provider recommends it to you, that is a defensible choice.

But the question underneath most Xeomin Miami searches is not really about Xeomin. It is: why isn’t this working like it used to, and what do I do about it? The answer is usually not a brand. It is a proper evaluation — dose, interval, technique, and a clear-eyed look at what is dynamic versus what is etched — followed by a plan built for how your face actually moves.

If a formulation without bacterial complexing proteins is what you want, we can offer that in Daxxify. And if what you actually need is a dosing correction with the product you already use, we will tell you that instead.

Wondering why your wrinkle relaxer isn’t lasting? Book a consultation at SkinUp in Kendall, Miami. We will look at the whole picture before recommending anything — refreshed, never overdone.

---

Disclaimer: This content is educational and is not a substitute for professional medical advice. Xeomin is a registered trademark of Merz; Botox of AbbVie/Allergan; Dysport of Ipsen/Galderma; Daxxify of Revance. Mention of a product does not imply it is available at SkinUp — our current neurotoxin menu is Botox, Dysport, and Daxxify. Individual results vary. All neurotoxins carry risks and contraindications, and a thorough consultation with a qualified, licensed provider is essential. Regulatory and clinical information reflects publicly available data as of August 2026.